| siRNA |
Anti-EGFR BsAb |
LCP NPs |
Light |
Methoxy group of PEG (mPEG) |
DSPE-mPEG2000, DSPE-PEG2000 folate, DSPE-PEG2000, DOPA, DOPC, and cholesterol |
40–50 |
−15 to −11 |
MDA-MB-468 cell line |
LCP NPs demonstrated prolonged circulation and enhanced tumor accumulation, achieving a concentration of 1.75% of the injected dose. Cellular uptake in MDA-MB-468 cells was significantly enhanced by up to threefold, and the siRNA release profile was pH-responsive, with around 50% released at pH 5.5 within 1 hour, and 90% by 10 hours. They also eliminated small and large tumors |
97
|
| 0.12–0.17 |
| — |
Trastuzumab |
NBs |
TUS |
Fc-G67 binding polypeptide |
DSPC, DSPE-PEG2000, and DSPE-PEG2000-Mal |
∼172 |
∼−22 |
SKOV3 and MDA-MB-231 cancer cells |
NBs remained visible in tumor vasculature on US imaging for up to 5 minutes post-injection, indicating short circulation time. Fluorescence imaging demonstrated strong binding to HER2-positive SKOV3 ovarian cancer cells and minimal binding to HER2-negative MDA-MB-231 cells, confirming targeted uptake |
65
|
| Narrow size distribution |
| — |
Anti-PD-L1 |
Liposomes |
UV |
DSPE-PEG2000 |
DPPC and DC8,9PC |
∼138 |
∼−3 |
CT26 cancer cells |
Their circulation half-life was extended to 18.3 ± 2.1 hours. Tumor accumulation was also substantially higher, with 2.1-fold greater fluorescence intensity in tumor tissues. Antitumor efficacy was marked by reduced tumor volume and extended survival (>20 days) |
73
|
| Low PDI |
